Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Robert A. Anders"'
Autor:
Teniola Oke, Thomas B. Schaffer, Evan J. Lipson, Dung T. Le, Christian F. Meyer, Lingling Chen, John Mc Mahon Gross, Laurene S. Cheung, Jillian T. Ngo, Nicolas J. Llosa, Janis M. Taube, Holly Kemberling, Karim Boudadi, John-William Sidhom, Robert A. Anders, Drew M. Pardoll, Luis A. Diaz
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Undifferentiated pleomorphic sarcoma (UPS), an aggressive soft-tissue sarcoma of adults, has been characterized by low tumor mutational burden (TMB) and high copy number alterations. Clinical trials of programmed death-1 (PD-1) blockade in UPS have r
Autor:
Nickolas Papadopoulos, Nianqing Xiao, Robert A. Anders, Kristen K. Ciombor, Shibin Zhou, Katherine M. Bever, Cara Wilt, Bao H. Lam, Hao Wang, Janis M. Taube, George A. Fisher, Matthias Holdhoff, Fay Wong, Richard M. Goldberg, Amanda N. Fader, Ludmila Danilova, Jennifer N. Durham, Laveet K. Aulakh, David Spetzler, Leslie Cope, Dung T. Le, Christian F. Meyer, Franck Housseau, James J. Lee, Aleksandra Eyring, Andrew K. Joe, James R. Eshleman, Deborah K. Armstrong, Bjarne Bartlett, Kellie N. Smith, Brandon Luber, Agnieszka A. Rucki, Daniel A. Laheru, Steve Lu, Nilofer S. Azad, Todd S. Crocenzi, Kenneth W. Kinzler, Tim F. Greten, Austin G. Duffy, Bert Vogelstein, Drew M. Pardoll, Luis A. Diaz, Atif Zaheer, Holly Kemberling, S. Peter Kang, Ross C. Donehower
Predicting responses to immunotherapy Colon cancers with loss-of-function mutations in the mismatch repair (MMR) pathway have favorable responses to PD-1 blockade immunotherapy. In a phase 2 clinical trial, Le et al. showed that treatment success is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee4527179e77e9a993495411588f44d3
https://europepmc.org/articles/PMC5576142/
https://europepmc.org/articles/PMC5576142/
Autor:
Darrell R. Borger, Timothy M. Pawlik, James M. Lindberg, Vikram Deshpande, Jean-François Gigot, Cristina R. Ferrone, Thomas Yau, Irinel Popescu, Aslam Ejaz, David Cosgrove, Todd W. Bauer, Robert A. Anders, Andrew X. Zhu, Christine Sempoux, T. Clark Gamblin, Ryan T. Groeschl, Ronnie T.P. Poon, Yuhree Kim, Sorin Alexandrescu
Publikováno v:
Annals of Surgical Oncology. 21:3827-3834
The molecular alterations that drive tumorigenesis in intrahepatic cholangiocarcinoma (ICC) remain poorly defined. We sought to determine the incidence and prognostic significance of mutations associated with ICC among patients undergoing surgical re
Autor:
Robert A. Anders, Rebecca M. Dodson, Justin Poling, Suresh K. Nayar, Ming Tseh Lin, James R. Eshleman, Omar Hyder, Scott P. Robertson, Timothy M. Pawlik, Katie Beierl
Publikováno v:
Human pathology. 44(12)
The incidence of intrahepatic cholangiocarcinoma is increasing worldwide. The prognosis of intrahepatic cholangiocarcinoma is poor, and a better understanding of intrahepatic cholangiocarcinoma tumor biology is needed to more accurately predict clini
Autor:
Georgios A. Margonis, Timothy M. Pawlik, Michael A. Choti, Rohan Gupta, Aslam Ejaz, Yuhree Kim, Georgios Karagkounis, Gaya Spolverato, Robert A. Anders, David Cosgrove
Publikováno v:
JAMA Surgery. 150:722
Surgical therapy, often combined with adjuvant systemic chemotherapy, is the best therapeutic option to treat patients with colorectal liver metastasis (CRLM), However, while overall survival (OS) has improved, many patients with CRLM will recur and
Autor:
Nick Papadopoulos, Timothy M. Pawlik, Michael A. Choti, Ralph H. Hruban, Xiaosong Zhang, Kenneth W. Kinzler, Shibin Zhou, Hong Zhao, Rajesh Kannangai, Michael Torbenson, Robert A. Anders, Bert Vogelstein, Laura D. Wood, Hubert Darius J. Daniel, Linfang Wang, G. Johan A. Offerhaus, Meng Li, Jianqiang Cai, Victor E. Velculescu
Publikováno v:
Nature Genetics. 43:828-829
Through exomic sequencing of ten hepatitis C virus (HCV)-associated hepatocellular carcinomas (HCC) and subsequent evaluation of additional affected individuals, we discovered novel inactivating mutations of ARID2 in four major subtypes of HCC (HCV-a